Medically reviewed by Dr. Mitesh Chandarana | Last updated: July 2026
If you or a family member has been on antipsychotic medication for months or years and has started developing involuntary movements – repetitive lip smacking, tongue movements, grimacing, or jerky limb movements – this could be tardive dyskinesia (TD). It’s a condition many patients and even some caregivers have never heard of until it appears, largely because it’s a delayed side effect that can show up long after a medication has seemingly been working well.
(Note: this is different from the dyskinesia sometimes seen in Parkinson’s disease as a side effect of long-term levodopa use – that’s a related but distinct phenomenon, discussed in our guide on PSP medications. This article focuses specifically on tardive dyskinesia caused by dopamine-blocking psychiatric medications.)
What Is Tardive Dyskinesia?
“Tardive” means delayed, and “dyskinesia” means abnormal, involuntary movement. Tardive dyskinesia is a movement disorder that develops as a side effect of long-term use of dopamine receptor-blocking medications – most commonly antipsychotics, but also certain anti-nausea drugs used long-term, like metoclopramide.
Unlike an acute drug reaction that appears within hours of taking a medication, TD typically develops only after months to years of continuous use though in some cases, it has been reported after as little as six weeks.
What Does It Look Like?
TD movements are typically:
- Repetitive and involuntary – the person cannot consciously stop them, though they may be able to briefly suppress movements with effort
- Often facial and oral first – lip smacking, puckering, tongue protrusion or “fly-catcher” tongue movements, grimacing, rapid blinking
- Sometimes involving limbs and trunk – jerky finger movements, foot tapping, rocking, or writhing movements
In my practice, one of the most important things I explain to families is that these movements typically occur during wakefulness and often subside during sleep – a helpful clue when distinguishing TD from other movement disorders that don’t follow this pattern.
Who Is at Risk?
Not everyone on long-term antipsychotic medication develops TD, but certain factors increase the risk:
- Duration and dose – longer treatment duration and higher cumulative doses raise risk
- Older antipsychotics (first-generation/typical) – medications like haloperidol, chlorpromazine, and fluphenazine carry meaningfully higher TD risk than newer options
- Newer antipsychotics (second-generation/atypical) – carry lower but non-zero risk; TD can still occur
- Age – older adults are at higher risk
- Sex – some studies suggest women, particularly post-menopausal women, may be at somewhat higher risk
- Underlying mood disorders – patients being treated for mood disorders alongside psychotic symptoms appear to carry additional risk compared to those treated for psychotic disorders alone
Why Early Recognition Matters
This is the single most important message I try to convey to patients and families: TD caught early is far more likely to improve than TD that’s gone unnoticed or unaddressed for years.
Once TD becomes established, particularly after prolonged exposure to the causative medication, the movements can become persistent – sometimes permanent – even after the medication is stopped or changed. This is why regular monitoring for anyone on long-term antipsychotic therapy matters, not just addressing it after it becomes visibly disruptive.
How Is Tardive Dyskinesia Diagnosed?
Diagnosis is primarily clinical, based on:
- A detailed medication history, including all current and past dopamine-blocking drugs and duration of use
- Observation of the specific movement pattern
- Ruling out other causes of involuntary movement including Huntington’s disease, other drug-induced movement disorders, and primary dystonias
- Standardized rating scales, such as the Abnormal Involuntary Movement Scale (AIMS), which some psychiatrists and neurologists use for periodic monitoring in patients on long-term antipsychotics
Treatment Approaches
1. Medication Review First
Where clinically appropriate and safe, reviewing whether the causative medication can be reduced, switched to a lower-risk alternative, or in some cases discontinued – always under close medical supervision, since abruptly stopping psychiatric medication can carry its own serious risks.
2. VMAT2 Inhibitors
Medications like valbenazine and deutetrabenazine are specifically approved for treating TD and work by reducing excess dopamine signaling at the level of the synapse. These have become a first-line treatment option in many cases where continuing the causative medication is necessary for the patient’s psychiatric stability.
3. Other Supportive Medications
In select cases, options like amantadine, clonazepam, or botulinum toxin injections (for more localized, severe movements) may be used, though evidence and use varies by individual presentation.
4. Deep Brain Stimulation
For severe, treatment-resistant TD significantly affecting quality of life, DBS has been used with some success in select cases, though this remains a less common, later-line option.
A Difficult Balance for Patients and Families
One of the genuine challenges with TD is that the causative medication is often essential for managing a serious underlying psychiatric condition – schizophrenia, bipolar disorder, or severe depression. This means treatment decisions require careful collaboration between the prescribing psychiatrist and a neurologist, weighing the risk of psychiatric relapse against the risk of worsening movement symptoms. This isn’t a decision to make in isolation, and it isn’t a decision that should be delayed once symptoms appear.
If you or a family member on long-term antipsychotic or dopamine-blocking medication has started developing unusual, repetitive involuntary movements, an evaluation with a neurologist alongside your treating psychiatrist can help determine the best path forward while symptoms are still in an earlier, more responsive stage.
Authoritative References
- MedlinePlus (NIH) – Tardive Dyskinesia
- American Academy of Neurology – Practice Guideline: Treatment of Tardive Syndromes
